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Akin Nihat1,2 and Simon Mead1,2*Editorial summary
Evidence has recently been reported of prion seeding
activity in skin tissue from patients with sporadic
Creutzfeldt-Jakob disease (sCJD). This is relevant
information for infection control measures during
surgery. The work uses very sensitive prion assays now
available for medical research, and may soon be
adapted to related neurodegenerative disorders.efficiency of transmission in an experiment: inoculation
route, PrP expression level of the inoculated animal,Prion diseases
Prion diseases are a group of incurable neurodegenera-
tive disorders marked by the accumulation of misfolded
forms of the normal cellular prion protein (PrP). The
concept of a proteinaceous pathogen or ‘prion’ respon-
sible for the transmissibility of the diseases, although ini-
tially controversial, has become an influential concept in
neurodegeneration research, but it is still unclear exactly
which structures of abnormal PrP behave as prions. The
most common human prion disease, sCJD, occurs at
random in the population. However, this disease group
is notorious for acquired forms: zoonotic variant CJD
(vCJD) arises following dietary exposure to bovine
spongiform encephalopathy (BSE) prions; and iatrogenic
CJD arises from exposure to prions as a result of a medical
procedure. Procedures known to have caused iatrogenic
CJD include the use of cadaveric growth hormone, dura
mater grafts, and, especially pertinent to a discussion
about prions in skin, surgical instruments. Extensive
measures are taken to prevent patient exposures to prions
during medical or surgical procedures in those asymptom-
atically infected, or with early but unrecognised symp-
toms. Acquired prion diseases are very rare. In 2017, 113
deaths were recorded in the UK from definite or probable* Correspondence: s.mead@prion.ucl.ac.uk
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acquired (National CJD Research and Surveillance Unit
data, https://www.cjd.ed.ac.uk/).Evidence for prions in skin
Animal bioassay is the only method to definitively dem-
onstrate prion infectivity, but these are expensive and
time-consuming experiments. Many factors affect the
prion strain (comparable to virus strain), and the degree
of homology in the primary sequence of PrP between
host and inoculum. By varying these factors, experi-
ments can be designed to optimise sensitivity, or model
medical situations more realistically. Recently, Orrú and
colleagues [1] demonstrated, for the first time, gold-
standard evidence for the presence of human prions in
skin, using a transmission study tuned to be sensitive: by
intracerebral inoculation of inocula made from the skin
of two patients with CJD, into mice that were engineered
to express the human form of PrP.
Surrogate methods were also used to infer the pres-
ence of prions in skin tissue. These methods do not
directly measure prion titres or infectivity but are fast,
inexpensive, and sensitive. The disease process generates
a multitude of abnormal forms of prion protein that can
be either infectious or non-infectious. Many abnormal
forms of prion protein have distinct biochemical proper-
ties such as relative protease resistance and staining
properties of amyloid protein aggregates, and can be de-
tected by histology or partial protease digestion and
Western blotting. Orrú et al. [1] found only a faint PrP-
immunoreactive band by Western blot from one of five
sCJD patients despite using enhanced detection tech-
niques. This finding is broadly consistent with previous
studies [2].
More significantly, Orrú et al. [1] employed in vitro prion
‘seeding’ assays, which are able to detect miniscule amounts
of disease-associated prion protein (~femtograms). The real-
time quaking-induced conversion (RTQuIC) assay exploitsle is distributed under the terms of the Creative Commons Attribution 4.0
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the misfolding of recombinant PrP through repeated cycles
of mechanical agitation intended to break apart the form-
ing amyloid. In a blinded analysis, Orrú et al. [1] demon-
strated by RTQuIC the presence of prion protein amyloid
in at least one of three skin samples from all 23 CJD pa-
tients with either vCJD or sCJD, but not in skin from any
non-CJD control individuals. The concentrations of
RTQuIC seeding activity were 1000- to 100,000-fold lower
in skin than brain tissue from the same patient. These
RTQuIC results are meaningful and quantitative, but a
caveat is that the assay can amplify non-infectious prion
protein aggregates; therefore, the assay results are a surro-
gate for prion titre only. Analysis of a larger dataset that
includes samples from healthy elderly individuals and/or
those with conditions that might be mistaken for CJD
would increase confidence in the specificity of this ap-
proach for CJD diagnosis.
Variant CJD infection has been transmitted by blood
or blood product transfusion on at least five occasions,
which has led to restrictions from the blood donor pool
for groups deemed to be at high risk. Approaches to
detect variant CJD prions in blood samples using protein
misfolding cyclic amplification (PMCA) have been de-
scribed in two recent papers [3, 4]. PMCA disrupts
aggregates using sonication rather than shaking, requires
a biological source for normal PrP rather than a recom-
binant protein, and uses Western blot as a readout. In
one study, blood from two donors who later developed
vCJD also demonstrated the presence of prions by
PMCA [4]. Data from these studies provide a key step
toward the validation of PMCA technology as a blood-
based diagnostic test for vCJD and support its potential
for detecting pre-symptomatic patients. However, the
prospect of using prion detection assays to ensure the
safety of blood transfusion is mitigated by several tech-
nical challenges that have yet to be overcome. Thank-
fully, there have been no patients diagnosed with blood-
transmitted variant CJD for 10 years.
Implications for infection control and diagnosis
Reports of prion transmissions, whether experimental or
observational, can sometimes result in excessive media
attention and misunderstandings. On occasion, notably
during the BSE crisis, media attention was justified and
major policy decisions needed to be taken. Our role as
research scientists is to carefully discuss the findings and
limitations of our results, even if not fully conclusive,
with the public and policymakers. Orrú and colleagues
[1] discuss their results responsibly; they emphasise that
prion disease is not known to be transmitted via casual
skin–skin contact, but they highlight the potential for
iatrogenic transmission from this tissue. They also
accept that the extreme sensitivity of the assays andmethodologies used, and low RTQuIC titres in skin rela-
tive to brain, makes the interpretation of these findings
in real-life infection control scenarios ambiguous. Fur-
ther animal bioassay studies of skin from patients with
sCJD may help to clarify the extent of infectivity.
Over 40 years ago, the demonstration of iatrogenic
neurosurgical transmission of CJD and the known resist-
ance of prions to standard decontamination methods
prompted epidemiological studies of surgery and risk of
CJD [5]. Most studies adopted a case–control method-
ology to identify patients diagnosed with CJD and retro-
spectively review their surgical histories compared with
matched controls. The results are inconclusive, which is
perhaps unsurprising in view of the inherent potential
for selection bias, recall bias, and that surgery may be
carried out to investigate unrecognised early symptoms
of CJD [5, 6].
What about CJD diagnosis? Skin biopsy samples in the
study by Orrú et al. [1] were obtained mostly from
deceased patients. It will be important to ascertain the
chronology; that is, whether prions accumulated as an
early or late feature of the disease. An earlier study by
Glatzel et al. [2] demonstrated that sCJD patients with the
highest level of abnormal PrP deposition in spleen and
skeletal muscle also had atypical forms and the longest
disease duration. Abnormal PrP has also been detected
using RTQuIC of material obtained by brushing the olfac-
tory mucosa in sCJD [7], and by adaptation of a blood-
based assay to urine [8]. However, although these findings
are insightful, the most reliable method of CJD diagnosis
is RTQuIC assay using cerebrospinal fluid obtained by
lumbar puncture and magnetic resonance brain imaging;
both of these techniques are sensitive and highly specific
and are a pre-requisite in the work-up of patients sus-
pected to have CJD to exclude other conditions [9].Conclusions and perspectives
Abnormal PrP amplification technologies are incredibly
sensitive assays that provide evidence for a wider tissue
distribution for prions in sCJD and rapid detection in
individual patients. Whether these developments will
translate into improved infection control measures is a
much more complicated question, as it is very hard to
find evidence for ongoing person–person transmission
with surgical instruments or blood–blood product trans-
fusion. This may be because transmissions are not cur-
rently occurring in healthcare settings, or a consequence
of the challenges of epidemiological investigation of a rare
disorder with potentially very long incubation periods. In
this context, any new infection control measures will need
to be practical and proportionate.
An increasing body of experimental and observational
evidence suggests that more common neurodegenerative
Nihat and Mead Genome Medicine  (2018) 10:22 Page 3 of 3diseases, such as Alzheimer’s and Parkinson’s diseases,
share fundamental mechanistic similarities with prion
disease [10]. Whilst these similarities were proposed
following animal transmission experiments and the
apparent spreading of protein pathologies in the brain,
recent findings raise the possibility of iatrogenic
amyloid-beta cerebral amyloid angiopathy in specific cir-
cumstances that parallel the experience of acquired
prion diseases [11]. This should neither be surprising
nor alarming news. In this respect, recent results illus-
trate the potential of tools developed for prion research
for the wider field of neurodegeneration and encourage
their adaptation to other misfolded proteins.
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